Castle Biosciences, Inc.

NASDAQ:CSTL

30.36 (USD) • At close September 18, 2024
Bedrijfsnaam Castle Biosciences, Inc.
Symbool CSTL
Munteenheid USD
Prijs 30.36
Beurswaarde 842,089,248
Dividendpercentage 0%
52-weken bereik 12.07 - 32.53
Industrie Diagnostics & Research
Sector Healthcare
CEO Mr. Derek J. Maetzold
Website https://castlebiosciences.com

An error occurred while fetching data.

Over Castle Biosciences, Inc.

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary

Vergelijkbare Aandelen

Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc.

FHTX

9.56 USD

Sangamo Therapeutics, Inc. logo

Sangamo Therapeutics, Inc.

SGMO

0.837 USD

The Pennant Group, Inc. logo

The Pennant Group, Inc.

PNTG

34.99 USD

Bioventus Inc. logo

Bioventus Inc.

BVS

11.69 USD

Surmodics, Inc. logo

Surmodics, Inc.

SRDX

39.3 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)